Satisfaction, subjective well-being and quality of life of schizophrenic patients under antipsychotics

The study aimed at evaluating schizophrenic patients’ subjective outcome concerning antipsychotics during in-patient care.

Methods: 162 out of 302 schizophrenic patients (ICD–10: F20) agreed to participate in the study (52,6%), 117 (72,2%) out of this sample completed the questionnaires (ZUF–8, SWN-K, WHOQOL-BREF, KKG and FKV-LIS). Variables of the German Basic Documentation (BADO) including CGI and GAF were additionally evaluated.

Results: 15.1% of patients received conventional antipsychotics (Haldoperidol, Fluphenazin, Flupentixol), 84.9% atypical antipsychotics (Clozapin, Amisulprid, Quetiapin, Risperidon, Olanzapin, Ziprasidon, Aripiprazol). 15.8% of patients got more than one antipsychotic. Using multiple linear regression analysis significant predictors for „satisfaction“–ZUF8 are the SWN-K subscales „self control“, „emotional regulation“ and „social integration“ and the WHOQOL-BREF domain „environment“ (R²=0.37). For the „subjective well-being under neuroleptica“ – SWN-K significant predictors are the WHOQOL-BREF domain „psychic“ and the FKV subscale „depressive processing“ (R²=0.55). Important predictors for „quality of life“ – WHOQOL-BREF are the SWN-K subscales „physical well-being“ and „social integration“ and the FKV subscale „religiosity and searching for sense of life“ (R²=0.47). Conventional or atypical antipsychotica were not found to be a relevant predictor for satisfaction, subjective well-being and quality of life, respectively.